Mylan launches chronic hepatitis B treatment tabs
The tablet has been launched in the strength of 25 mg
Drug firm Mylan Pharmaceuticals has launched tenofovir alafenamide tablets under the brand name ‘HepBest’, used for treatment of chronic hepatitis B in adults, in India. HepBest is the first drug in eight years to be approved for the management of chronic hepatitis B in India, Mylan Pharmaceuticals said in a statement. The tablet has been launched in the strength of 25 mg, it added.
Commenting on the development, Rakesh Bamzai, President, Mylan India and Emerging Markets said, “Mylan continues to be in the forefront of introducing new treatment regimens for the management of hepatitis in India.” By bringing the best-in-class drug for hepatitis B management, HepBest, to India, Mylan hopes to provide care for chronic hepatitis B patients and improve overall management of the disease, he added.